Synlogic presents data from synb1891 phase 1 trial at american association for cancer research (aacr) annual meeting

Cambridge, mass., april 10, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on synb1891 for the treatment of solid tumors and lymphoma during the american association for cancer research (aacr) annual meeting, april 10-15, 2021.
SYBX Ratings Summary
SYBX Quant Ranking